NFL Biosciences

Recent Finacing

Debt

Recent Raise

$0.6M

NFL Biosciences is a biopharmaceutical company developing NFL-102, a novel therapeutic targeting the biological mechanisms that sustain nicotine addiction.

Founded 2009

Languedoc-Roussillon, France

1-10

Publicly Traded

nflbiosciences.com

Highlights

Focus Areas

Biotechnology

Medical

Pharmaceutical

Recent Investors

Financials

$2M

Total Raised

2

Funding rounds

3

Investors

Team

Upgrade to view the team

See the team members at NFL Biosciences.